Negative association between serum aryl hydrocarbon receptor concentrations and β‐cell function in patients with no history of diabetes undergoing coronary angiography

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The aim of the present study was to investigate the association between serum aryl hydrocarbon receptor (AhR) levels and insulin resistance and β‐cell function in patients undergoing coronary angiography with no history of diabetes.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients with no history of diabetes who had undergone coronary angiography underwent an oral glucose tolerance test (OGTT) 2–4 weeks after discharge from hospital; blood samples were collected for measurements of glucose, insulin, and AhR. Patients’ glucose regulation status was determined on the basis of the OGTT. Insulin resistance was assessed using the homeostasis model assessment of insulin resistance (HOMA‐IR). β‐Cell function was assessed using the insulinogenic index (IGI).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The study included 473 patients (mean (±SD) age 61 ±12 years, 81.8% male, mean body mass index 26.1 ±3.6 kg/m<jats:sup>2</jats:sup>). Overall, mean serum AhR concentrations were 25.1 ±12.2 pg/mL. Patients with normal glucose tolerance had a lower serum AhR concentrations than patients with prediabetes or newly diagnosed diabetes (23.4 ±10.8 vs 26.2 ±13.2 and 26.9 ±12.3 pg/mL, respectively; <jats:italic>P =</jats:italic> 0.029). Linear regression analysis revealed that serum AhR concentrations were not associated with HOMA‐IR, but were negatively associated with IGI after adjustment for several confounders, including HOMA‐IR (β = −0.162; 95% confidence interval − 0.302, −0.022; <jats:italic>P =</jats:italic> 0.023).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In patients with no history of diabetes, serum AhR concentrations were negatively associated with β‐cell function, independent of several confounders, including insulin resistance.</jats:p></jats:sec>